The company intends to provide a simple blood test for the early detection of ovarian cancer. Credit: Ahmad Ardity from Pixabay.

Cleo Diagnostics has received a patent from the US Patent and Trademark Office (USPTO) for its new biomarker for ovarian cancer.

The CXCL10 Binding Proteins and Compositions Thereof patent encompasses Cleo’s proprietary biomarkers and antibody formulations, which include the essential technology of the company’s blood test designed for ovarian cancer.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

This patent portfolio focuses on binding proteins for C‐X‐C motif chemokine ligand 10 (CXCL10) and techniques for diagnosing a condition, such as malignancy. This includes the assessment of the CXCL10 level in a subject.

For monitoring tumour burden, malignancy progression, or the likelihood of tumour recurrence in a patient, determining the CXCL10 level can also be utilised.

The patent broadens Cleo’s portfolio of intellectual property (IP), adding to the patent received earlier this year in Australia.

See Also:

More patent applications are presently pending in India, Korea, Japan, China, Singapore, New Zealand, Israel and Europe.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Cleo CEO Richard Allman said: “Securing a US patent not only expands the company’s IP portfolio, but it also marks an important milestone which effectively activates our commercialisation plans to pursue market entry in the largest diagnostics market in the world.

“Cleo’s simple blood test for accurate and early detection of ovarian cancer has the potential to transform the standard of care for women globally.”

The goal of the company is to introduce a simple blood test that utilises the patented CXCL10 biomarker for the precise and early detection of ovarian cancer.